Printer Friendly

Insmed Receives FDA Orphan Drug Designation For rhIGF-I/rhIGFBP-3, SomatoKine, for Extreme Insulin Resistance.

Business Editors/Health/Medical Writers


RICHMOND, Va.--(BUSINESS WIRE)--Dec. 15, 2003

Insmed Incorporated (Nasdaq: INSM) today announced that the Office of Orphan Products Development of the Food and Drug Administration has approved the Company's application for orphan drug designation in the United States for SomatoKine(R), for the treatment of extreme insulin resistance. With this orphan drug designation, Insmed will be granted seven years of market exclusivity upon SomatoKine(R) approval for this indication. There is currently no approved treatment available for patients with extreme insulin resistance in the United States.

Insmed's investigational drug rhIGF-I/rhIGFBP-3, SomatoKine(R), is a proprietary delivery composition of insulin like growth factor-I (IGF-I). This drug is administered as a once-daily subcutaneous injection and is designed to restore IGF-I levels to more normal ranges in metabolic and anabolic disorders where IGF deficiency exists. Insmed is currently developing rhIGF-I/rhIGFBP-3 for the treatment of severe growth disorders and diabetes.

More on Extreme Insulin Resistance

Syndromes of Extreme Insulin Resistance appear to result from genetic defects in the insulin receptor or insulin action pathways. In addition to insulin resistance and glucose intolerance or overt diabetes, these syndromes share a number of common features including variable degrees of hyperandrogenism, hirsutism, and dysmorphic features.

More on rhIGF-I/rhIGFBP-3, SomatoKine(R)

Insmed's rhIGF-I/rhIGFBP-3 is a proprietary delivery composition of insulin-like growth factor-I (IGF-I). The novel compound is administered as a once-daily subcutaneous injection, which can restore IGF levels to physiological relevant levels. In diabetic subjects, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in blood sugar control and a significant reduction in daily insulin use. Following severe burn injury, in both children and adults, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in muscle protein synthesis and a significant reduction in the inflammatory response associated with the trauma. In recovery from hip fractures, administration of rhIGF-I/rhIGFBP-3 has demonstrated a significant improvement in functional recovery and bone mineral density. rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS), a severe growth disorder.

About Insmed Incorporated

Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 15, 2003
Previous Article:Neuberger Berman Closed-End Intermediate Municipal Funds Declare Monthly Dividends.
Next Article:NASCAR Silicon Motor Speedway's Sixth Revenue Share to Be Featured Attraction of New Burdick Driver's Village.

Related Articles
Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders.
Insmed Receives European Orphan Drug Designation For rhIGF-I/rhIGFBP-3; Product Will Have 10 Years of Market Exclusivity in Treatment of Growth...
Insmed Launches Pivotal Phase III Clinical Trial in GHIS; Data Analysis Planned for Early 2004.
Insmed Obtains Patent Rights for Extreme Insulin Resistance From Fujisawa.
Insmed Acquires Manufacturing Facility from Baxter International.
Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European...
Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director.
Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine.
Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome.
Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters